Evotec SE

EVT.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVT.DE stands at 1.36B. In comparison, ZOE.DE has a market cap of 63.15B. Regarding current trading prices, EVT.DE is priced at $7.65, while ZOE.DE trades at $141.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVT.DE currently has a P/E ratio of -6.54, whereas ZOE.DE's P/E ratio is 28.89. In terms of profitability, EVT.DE's ROE is -0.19%, compared to ZOE.DE's ROE of +0.50%. Regarding short-term risk, EVT.DE is more volatile compared to ZOE.DE. This indicates potentially higher risk in terms of short-term price fluctuations for EVT.DE.

EVT.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVT.DE stands at 1.36B. In comparison, MRK.DE has a market cap of 52.36B. Regarding current trading prices, EVT.DE is priced at $7.65, while MRK.DE trades at $123.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVT.DE currently has a P/E ratio of -6.54, whereas MRK.DE's P/E ratio is 19.30. In terms of profitability, EVT.DE's ROE is -0.19%, compared to MRK.DE's ROE of +0.10%. Regarding short-term risk, EVT.DE is more volatile compared to MRK.DE. This indicates potentially higher risk in terms of short-term price fluctuations for EVT.DE.

EVT.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVT.DE stands at 1.36B. In comparison, DMP.DE has a market cap of 2.13B. Regarding current trading prices, EVT.DE is priced at $7.65, while DMP.DE trades at $39.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVT.DE currently has a P/E ratio of -6.54, whereas DMP.DE's P/E ratio is 18.74. In terms of profitability, EVT.DE's ROE is -0.19%, compared to DMP.DE's ROE of +0.20%. Regarding short-term risk, EVT.DE is more volatile compared to DMP.DE. This indicates potentially higher risk in terms of short-term price fluctuations for EVT.DE.

EVT.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVT.DE stands at 1.36B. In comparison, 2HQ.DE has a market cap of 387.83M. Regarding current trading prices, EVT.DE is priced at $7.65, while 2HQ.DE trades at $0.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVT.DE currently has a P/E ratio of -6.54, whereas 2HQ.DE's P/E ratio is -0.40. In terms of profitability, EVT.DE's ROE is -0.19%, compared to 2HQ.DE's ROE of -0.29%. Regarding short-term risk, EVT.DE is more volatile compared to 2HQ.DE. This indicates potentially higher risk in terms of short-term price fluctuations for EVT.DE.

EVT.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVT.DE stands at 1.36B. In comparison, PSG.DE has a market cap of 308.54M. Regarding current trading prices, EVT.DE is priced at $7.65, while PSG.DE trades at $26.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVT.DE currently has a P/E ratio of -6.54, whereas PSG.DE's P/E ratio is 17.07. In terms of profitability, EVT.DE's ROE is -0.19%, compared to PSG.DE's ROE of +0.49%. Regarding short-term risk, EVT.DE is more volatile compared to PSG.DE. This indicates potentially higher risk in terms of short-term price fluctuations for EVT.DE.

EVT.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVT.DE stands at 1.36B. In comparison, HAEK.DE has a market cap of 111.50M. Regarding current trading prices, EVT.DE is priced at $7.65, while HAEK.DE trades at $21.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVT.DE currently has a P/E ratio of -6.54, whereas HAEK.DE's P/E ratio is 11.57. In terms of profitability, EVT.DE's ROE is -0.19%, compared to HAEK.DE's ROE of +0.06%. Regarding short-term risk, EVT.DE is more volatile compared to HAEK.DE. This indicates potentially higher risk in terms of short-term price fluctuations for EVT.DE.

EVT.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVT.DE stands at 1.36B. In comparison, 93M1.DE has a market cap of 103.61M. Regarding current trading prices, EVT.DE is priced at $7.65, while 93M1.DE trades at $24.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVT.DE currently has a P/E ratio of -6.54, whereas 93M1.DE's P/E ratio is 0.87. In terms of profitability, EVT.DE's ROE is -0.19%, compared to 93M1.DE's ROE of +0.41%. Regarding short-term risk, EVT.DE is more volatile compared to 93M1.DE. This indicates potentially higher risk in terms of short-term price fluctuations for EVT.DE.

EVT.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVT.DE stands at 1.36B. In comparison, APPH.DE has a market cap of 92.88M. Regarding current trading prices, EVT.DE is priced at $7.65, while APPH.DE trades at $11.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVT.DE currently has a P/E ratio of -6.54, whereas APPH.DE's P/E ratio is 123.89. In terms of profitability, EVT.DE's ROE is -0.19%, compared to APPH.DE's ROE of +0.02%. Regarding short-term risk, EVT.DE is more volatile compared to APPH.DE. This indicates potentially higher risk in terms of short-term price fluctuations for EVT.DE.

EVT.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVT.DE stands at 1.36B. In comparison, B8F.DE has a market cap of 20.67M. Regarding current trading prices, EVT.DE is priced at $7.65, while B8F.DE trades at $6.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVT.DE currently has a P/E ratio of -6.54, whereas B8F.DE's P/E ratio is -32.40. In terms of profitability, EVT.DE's ROE is -0.19%, compared to B8F.DE's ROE of +0.18%. Regarding short-term risk, EVT.DE is less volatile compared to B8F.DE. This indicates potentially lower risk in terms of short-term price fluctuations for EVT.DE.

EVT.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVT.DE stands at 1.36B. In comparison, 21P1.F has a market cap of 19.64M. Regarding current trading prices, EVT.DE is priced at $7.65, while 21P1.F trades at $0.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVT.DE currently has a P/E ratio of -6.54, whereas 21P1.F's P/E ratio is -0.01. In terms of profitability, EVT.DE's ROE is -0.19%, compared to 21P1.F's ROE of -0.06%. Regarding short-term risk, EVT.DE is more volatile compared to 21P1.F. This indicates potentially higher risk in terms of short-term price fluctuations for EVT.DE.

EVT.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVT.DE stands at 1.36B. In comparison, SBX.DE has a market cap of 17.78M. Regarding current trading prices, EVT.DE is priced at $7.65, while SBX.DE trades at $3.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVT.DE currently has a P/E ratio of -6.54, whereas SBX.DE's P/E ratio is -1.42. In terms of profitability, EVT.DE's ROE is -0.19%, compared to SBX.DE's ROE of -0.55%. Regarding short-term risk, EVT.DE is more volatile compared to SBX.DE. This indicates potentially higher risk in terms of short-term price fluctuations for EVT.DE.

EVT.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVT.DE stands at 1.36B. In comparison, HOB0.F has a market cap of 17.00M. Regarding current trading prices, EVT.DE is priced at $7.65, while HOB0.F trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVT.DE currently has a P/E ratio of -6.54, whereas HOB0.F's P/E ratio is 6.30. In terms of profitability, EVT.DE's ROE is -0.19%, compared to HOB0.F's ROE of -1.18%. Regarding short-term risk, EVT.DE is more volatile compared to HOB0.F. This indicates potentially higher risk in terms of short-term price fluctuations for EVT.DE.

EVT.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVT.DE stands at 1.36B. In comparison, Z6A.F has a market cap of 4.52M. Regarding current trading prices, EVT.DE is priced at $7.65, while Z6A.F trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVT.DE currently has a P/E ratio of -6.54, whereas Z6A.F's P/E ratio is -0.02. In terms of profitability, EVT.DE's ROE is -0.19%, compared to Z6A.F's ROE of -0.23%. Regarding short-term risk, EVT.DE is more volatile compared to Z6A.F. This indicates potentially higher risk in terms of short-term price fluctuations for EVT.DE.

EVT.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVT.DE stands at 1.36B. In comparison, PA8.DE has a market cap of 2.71M. Regarding current trading prices, EVT.DE is priced at $7.65, while PA8.DE trades at $0.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVT.DE currently has a P/E ratio of -6.54, whereas PA8.DE's P/E ratio is -0.13. In terms of profitability, EVT.DE's ROE is -0.19%, compared to PA8.DE's ROE of -0.09%. Regarding short-term risk, EVT.DE is less volatile compared to PA8.DE. This indicates potentially lower risk in terms of short-term price fluctuations for EVT.DE.

EVT.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVT.DE stands at 1.36B. In comparison, 2NU.F has a market cap of 1.08M. Regarding current trading prices, EVT.DE is priced at $7.65, while 2NU.F trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVT.DE currently has a P/E ratio of -6.54, whereas 2NU.F's P/E ratio is -0.03. In terms of profitability, EVT.DE's ROE is -0.19%, compared to 2NU.F's ROE of N/A. Regarding short-term risk, EVT.DE is less volatile compared to 2NU.F. This indicates potentially lower risk in terms of short-term price fluctuations for EVT.DE.

EVT.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVT.DE stands at 1.36B. In comparison, ERV2.F has a market cap of 312475.00. Regarding current trading prices, EVT.DE is priced at $7.65, while ERV2.F trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVT.DE currently has a P/E ratio of -6.54, whereas ERV2.F's P/E ratio is -0.02. In terms of profitability, EVT.DE's ROE is -0.19%, compared to ERV2.F's ROE of +2.97%. Regarding short-term risk, EVT.DE is more volatile compared to ERV2.F. This indicates potentially higher risk in terms of short-term price fluctuations for EVT.DE.

EVT.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVT.DE stands at 1.36B. In comparison, MCD.DE comparison data is unavailable. Regarding current trading prices, EVT.DE is priced at $7.65, while MCD.DE trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVT.DE currently has a P/E ratio of -6.54, whereas MCD.DE's P/E ratio is -0.02. In terms of profitability, EVT.DE's ROE is -0.19%, compared to MCD.DE's ROE of -1.69%. Regarding short-term risk, EVT.DE is less volatile compared to MCD.DE. This indicates potentially lower risk in terms of short-term price fluctuations for EVT.DE.

EVT.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVT.DE stands at 1.36B. In comparison, 4XT.DE comparison data is unavailable. Regarding current trading prices, EVT.DE is priced at $7.65, while 4XT.DE trades at $0.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVT.DE currently has a P/E ratio of -6.54, whereas 4XT.DE's P/E ratio is -2.18. In terms of profitability, EVT.DE's ROE is -0.19%, compared to 4XT.DE's ROE of -7.27%. Regarding short-term risk, EVT.DE is more volatile compared to 4XT.DE. This indicates potentially higher risk in terms of short-term price fluctuations for EVT.DE.

EVT.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVT.DE stands at 1.36B. In comparison, BIO1.F comparison data is unavailable. Regarding current trading prices, EVT.DE is priced at $7.65, while BIO1.F trades at $36.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVT.DE currently has a P/E ratio of -6.54, whereas BIO1.F's P/E ratio is -22.85. In terms of profitability, EVT.DE's ROE is -0.19%, compared to BIO1.F's ROE of +0.26%. Regarding short-term risk, EVT.DE is more volatile compared to BIO1.F. This indicates potentially higher risk in terms of short-term price fluctuations for EVT.DE.